Summary
Global
Markets Direct's, 'Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase
13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Pipeline
Review, H1 2016', provides in depth analysis on Aurora Kinase C (Aurora 3 or
Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C
or EC 2.7.11.1) targeted pipeline therapeutics.
The
report provides comprehensive information on the Aurora Kinase C (Aurora 3 or
Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C
or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications,
stage of development, mechanism of action (MoA), route of administration (RoA)
and molecule type. The report also covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and
latest news and press releases. Additionally, the report provides an overview
of key players involved in Aurora Kinase C (Aurora 3 or
Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C
or EC 2.7.11.1) targeted therapeutics development and features dormant and
discontinued projects.
Global
Markets Direct's report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
Note*: Certain
sections in the report may be removed or altered based on the availability and
relevance of data.
Buy a Sample Copy
of This Report @ http://www.radiantinsights.com/research/aurora-kinase-c-aurora-3/request-sample
No comments:
Post a Comment